Eczema Trial, Recruiting NCT07467564 Sponsor: Sanofi Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT07467564
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have moderate to severe atopic dermatitis (a type of chronic skin condition) along with signs of anxiety and/or depression.
  • People whose doctor has decided to start them on a medication called dupilumab within 30 days of joining the study, as a treatment decision made independently of the trial.
  • People who are willing to sign a consent form agreeing to take part (for younger participants, a parent or legal guardian may sign on their behalf).

Who may not be able to join:

  • Females who are currently pregnant, breastfeeding, or planning to become pregnant within the next 6 months.
  • People who are already taking part in another clinical trial.
  • People who currently have an ongoing or sudden infection that requires treatment taken by mouth or injection (such as antibiotics or antivirals).
  • People who have an active internal parasitic infection, or who are considered to be at high risk of getting one.
  • People who have HIV, hepatitis B or C, cancer, or certain other serious ongoing health conditions.
  • People who have taken medication for depression or anxiety in the 6 months before joining the trial, or who are planning to take such medication during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 February 2026
Est. completion
24 May 2027

Where this trial is recruiting

Qatar 🇸🇦 Saudi Arabia 🇦🇪 United Arab Emirates

Primary endpoints

Proportion of Participants with Hospital Anxiety and Depression Scale Anxiety (HADS-A) Sub-scores of Less Than 8; Proportion of Participants with HADS Depression (HADS-D) Sub-scores of less than 8; Change from Baseline in HADS Total Score.; Proportion of Participants with More Than or Equal to 4-point Improvement in POEM Total Score; Change from Baseline in POEM Total Score.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov